Clinical Trials
14 trialsNCT05052528 2024-05-13
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of California, Davis
Phase 1 Unknown
NCT05420493 2024-01-05
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT05979792 2023-08-21
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Ruijin Hospital
Phase EARLY_PHASE1 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT02186860 2021-02-10
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT04534634 2020-09-01
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04206943 2020-01-27
ISIKOK-19
Acibadem University
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02965092 2019-05-10
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Phase 1/2 Unknown
NCT03881774 2019-03-21
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
Phase 1 Unknown
NCT02819583 2016-10-25
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02851589 2016-08-01
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02315118 2016-06-22
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
Phase 1/2 Unknown